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Summary Introduction
Batten disease (juvenile-onset neuronal ceroid lipofus-Batten disease (juvenile-onset neuronal ceroid lipofus-
cinosis [JNCL], or Spielmeyer-Vogt-Sjo¨gren diseasecinosis [JNCL]) is an autosomal recessive condition
[MIM 304200]) is the most common inherited neurode-characterized by accumulation of lipopigments (lipofus-
generative disease of childhood. Inheritance is autoso-cin and ceroid) in neurons and other cell types. The
mal recessive, and its incidence is estimated as being asBatten disease gene, CLN3, was recently isolated, and
high as 1/25,000 births, with an increased prevalence infour disease-causing mutations were identiﬁed, includ-
northern-European populations (Zeman 1974). The ﬁrsting a 1.02-kb deletion that is present in the majority of
clinical symptom is visual failure, which occurs at thepatients (The International Batten Disease Consortium
age of 4–7 years. Mental retardation, epilepsy, and psy-1995). One hundred eighty-eight unrelated patients with
chomotor deterioration manifest later, eventually lead-JNCL were screened in this study to determine how
ing to death in the 2d or 3d decade of life. Diagnosticmany disease chromosomes carried the 1.02-kb deletion
criteria include macular degeneration, the presence ofand how many carried other mutations in CLN3. One
vacuolated lymphocytes in peripheral blood, and thehundred thirty-nine patients (74%) were found to have
accumulation of autoﬂuorescent lipopigments (ceroidthe 1.02-kb deletion on both chromosomes, whereas 49
and lipofuscin) in neurons and other cell types, which,patients (41 heterozygous for the 1.02-kb deletion) had
on electron microscopy, appear as ﬁngerprint proﬁlesmutations other than the 1.02-kb deletion. SSCP analy-
(Santavuori 1988). The biochemical defect underlyingsis and direct sequencing were used to screen for new
the disease is unknown.mutations in these individuals. Nineteen novel muta-
Following assignment of CLN3, the gene for Battentions were found: six missense mutations, ﬁve nonsense
disease, to chromosome 16 (Eiberg et al. 1989), reﬁne-mutations, three small deletions, three small insertions,
ment of localization was achieved by further genetic-one intronic mutation, and one splice-site mutation.
linkage studies, analysis of haplotypes, and linkage-dis-This report brings the total number of disease-associated
equilibrium mapping (Callen et al. 1991; Gardiner et al.mutations in CLN3 to 23. All patients homozygous for
1990; Mitchison et al. 1993, 1994, 1995; Yan et al.mutations predicted to give rise to truncated proteins
1993; Lerner et al. 1994). The CLN3 gene, isolated inwere found to have classical JNCL. However, a propor-
1995, encodes a predicted protein of 438 amino acidstion of the patients (n Å 4) who were compound hetero-
that has no homology to any proteins of known functionzygotes for a missense mutation and the 1.02-kb deletion
(The International Batten Disease Consortium 1995).were found to display an atypical phenotype that was
Four different mutations were critical in identifyingdominated by visual failure rather than by severe neuro-
CLN3—three intragenic genomic deletions and a pointdegeneration. All missense mutations were found to af-
mutation that affects a splice site. A deletion of 1.02 kbfect residues conserved between the human protein and
is the most common mutation in CLN3; it is present onhomologues in diverse species.
81% of disease chromosomes (The International Batten
Disease Consortium 1995). Our aim in this study was
to identify the remaining mutations in our resource of
188 unrelated JNCL patients.
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Table 1different countries (43 patients from Finland, 34 pa-
tients from the United States, 25 patients from the Neth-
CLN3 Primers Used for Exon Ampliﬁcation
erlands, 23 patients from Germany, 15 patients from the
United Kingdom, 14 patients from Norway, 13 patients Sense Antisense Length
Exon (5r3) (5r3) (bp)from Denmark, 5 patients from Sweden, 4 patients from
Italy, 3 patients from Greece, 2 patients from Australia,
1 aaaggtacaggcctcagggt agctctcattcccctcaggt 381and 1 patient each from Portugal, Austria, Belgium,
2 acctgagggaatgagagct tgggttcagctcctttgc 285
Newfoundland, New Zealand, Morocco, and Iceland). 3 attgaagggcataggtaaga actttaccccaccttgtccc 266
One hundred eighty-four patients presented with clas- 4 tcaagtgaaggcagagctgg agtcccagctgggtagtgaa 251
5 cctgtgtttgtagcaggcct aaggtcggtctctactctcagc 281sical JNCL: disease course characterized by the onset of
6 tggtcaggagctgagaaagg gaatccctttcctctgggag 275visual disorder at age 6.2 { 1.8 years; dementia at age
7 ggagcctctatgagctgatactg ggaacattcaggaggacctagg 2507.4 { 2 years; seizures and motor disturbance at age
8 tgtcccatggtcagcctag ttctctccttggacccctct 241
9.5 { 3.5 years, with onset of a vegetative state at age 9 gcagtgagctacccatcttt aggaaaaggccaaacccag 301
18.4 { 2.8 years; and death at age 20.2 { 6.3 years 10 aatccagtggcatggaagttg ctacgaccaagggaacaat 287
11 tcgggaaaggtggacagta ggtattgctgagcgtgactc 318(Wisniewski et al. 1988). Diagnosis was conﬁrmed by
12 tcgggaaaggtggacagta aggtgaaacggatgcgac 526the identiﬁcation of vacuolated lymphocytes and dem-
13 tttgaactcctctttttctgg acactttccactgatagtggga 376onstration of ultrastructural ﬁngerprint proﬁles with or
14 tcctaaaaccagggacccct ttcagtcccagacatccctg 303
without curvilinear bodies, on electron microscopy 15 agggatgtctgggactgaag ggcatgatgccaggaaga 374
(EM) of neural or extraneural tissues.
a Same primer.Four patients presented with an atypical disease
course. Patient L39Pa (who died at age 25 years), from
the Netherlands, had a severe visual and moderate sei-
zure disorder, with typical motor dysfunction, but had 1.02-kb–Deletion Assay
minimal speech retardation and remained conversant Three PCR-based methods were used to detect the
until the terminal stages of the disease. Patients L204Pa 1.02-kb genomic deletion: primers F2 and P3, described
and L285Pa are both under the care of one physician previously (The International Batten Disease Consor-
(Dr. Pirkko Santavuori, University of Helsinki Clinic tium 1995; Munroe et al. 1996), were used to amplify
and Children’s Hospital, Helsinki). Patient L204Pa, now DNA surrounding the deletion; in cases in which, be-
15 years old, presented with visual failure at age 6 years cause of the age and quality of patient DNA, long-range
when ophthalmological examination revealed severe ret- PCR was not possible, either primers F2 and R1 (5-
inal dystrophy and mild macular changes. This ﬁnding agtgagggagaggaaggtga-3) or primers that amplify exon
was considered to be slightly atypical of JNCL. To date, 7 (table 1) were used to check for the absence of exon
the patient has not experienced any epileptic ﬁts. Vacuo- 7. Positive controls for PCR of other CLN3 exons were
lated lymphocytes were found in repeated examinations, included.
and the EM ﬁndings from a rectal biopsy revealed the
presence of both curvilinear and ﬁngerprint patterns. PCR Ampliﬁcation of Exons
Patient L285Pa, now 30 years old, presented with visual Primers to amplify each exon and the surrounding
failure at age 6 years and became virtually blind at age intron sequence (table 1) were designed from genomic
13 years. This patient displays no other clinical signs of DNA sequence of CLN3 (Mitchison et al. 1997). PCR
the disease, has completed high school education, and was performed in a ﬁnal volume of 100 ml, by use of
now runs a business. Vacuolated lymphocytes were 100 ng of genomic DNA, 0.2 mM each primer, 0.25 mM
found in repeated examinations, and EM ﬁndings of a each dNTP, 1.5 mM MgCl2 and 1.5 units of AmpliTaq
rectal biopsy found inclusions typical of neuronal ceroid (Perkin-Elmer). A ‘‘hot’’ start was performed, followed
lipofuscinosis. Patient L46Pb, from the United King- by 30 cycles of 1 min at 94C, 1 min at 60C, and 1
dom, now 22 years old, presented with visual loss at min at 72C and then by a ﬁnal cycle of 10 min at 72C,
age 10 years and had severe visual impairment by age by use of Hybaid OmniGene. The resulting products
12 years. The patient remained well until the onset of were electrophoresed in 1% agarose gels and, after
seizures at age 18 years; however, the patient has no ethidium bromide staining, were visualized with a UV
evidence of motor dysfunction or regression. The patient transilluminator.
has now completed college education and is now in full-
SSCP Analysistime employment. Diagnosis of JNCL was conﬁrmed by
both the presence of vacuolated lymphocytes and the Two different systems were used for the detection of
SSCPs. The ﬁrst used the Phastsystem (Pharmacia),EM ﬁnding of ﬁngerprint inclusions in lymphocytes. Ge-
nomic DNA was extracted directly from peripheral which has been described elsewhere (The International
Batten Disease Consortium 1995). Gels were electro-blood or from lymphoblastoid cell lines, by use of stan-
dard methods. phoresed for 300 Vh at 4C and for 200 Vh at 15C
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in this study. The second method used a radioactive than the 1.02-kb deletion; the mutations in three of these
have been reported elsewhere (The International Battenprotocol, and samples were analyzed on MDETM high-
resolution gels (AT Biochem). Disease Consortium 1995).
Direct DNA Sequencing Mutational Analysis
Ampliﬁed exon products to be sequenced were de- Forty-six patients were screened for new mutations.
salted and concentrated by use of Microcon-100 col- All 15 exons of the gene were ampliﬁed: SSCP analysis
umns (Amicon). Sequencing was performed with the was performed on exons 7 and 8, and any band shifts
same primers as were used for exon ampliﬁcation, by were subsequently sequenced. All remaining exons were
use of the Taq FS Dye Terminator Cycle sequencing kit sequenced in both directions. Nineteen novel mutations
(Perkin-Elmer), and automated analysis was done with were identiﬁed: six missense mutations, ﬁve nonsense
the ABI 373A sequencer. All exons were sequenced in mutations, three small deletions, three small insertions,
both directions, and sequence comparisons were per- one intronic mutation, and one splice-site mutation (ta-
formed by use of Sequence Navigator software (Perkin- ble 2 and ﬁg. 1). None of the missense mutations or
Elmer) and manual scanning. In one laboratory, the ex- the intron mutation was found on 90 chromosomes of
ons were sequenced manually (Sanger et al. 1977) with unaffected control individuals, which suggests that these
Sequenase T7 DNA polymerase (United States Biochem- changes do not represent frequent polymorphisms. In-
icals). heritance of the mutation in family members was
checked by use of a restriction-digest test, if one was
RNA Extraction and Analysis available. If the mutation did not affect a restriction site,
Cytoplasmic RNA was isolated by use of standard DNA from family members was sequenced. Mendelian
methods (Sambrook et al. 1989). RNA was reverse tran- inheritance of mutations was observed (table 2).
scribed by use of oligo(dT) and Superscript reverse tran- Cell lines were available from the patients with the
scriptase (Gibco-BRL). Primers 6972 (5-aaattgttggct- intronic and the splice-site mutations; therefore RNA
cctcttgg-3) and 6700 (5-gcgctctctgcttcttcttc-3) were was tested to conﬁrm the predicted effects of the muta-
used to amplify the RNA-cDNA duplex from patient tions. Patient L121Pa/BA, heterozygous for the 1.02-kb
L121/BA. Primers 6795 (5-ttgatccttgtcacctgtcg-3) and deletion and the intronic substitution (IVS6-13GrC),
6797 (5-attcagaaggcatgahtgcc-3) were used to amplify was subjected to reverse-transcriptase PCR (RT-PCR)
the RNA-cDNA duplex from patient BB, followed by analysis using primers that ampliﬁed exons 5–9. Three
ampliﬁcation using nested primers 6972 and 6333 (5- PCR products were ampliﬁed: the expected normal size
ggctgggagcacagttcat-3). All products were subcloned (409 bp), a product of 265 bp, and a product of 220 bp.
and sequenced. Sequencing revealed the largest band to be the correctly
spliced normal sequence, whereas the 265-bp product
Restriction-Endonuclease Analysis was found to be missing exon 7, and the 220-bp product
Ampliﬁed exon products were digested according to was missing exons 7 and 8 (corresponding to the 1.02-
the manufacturer’s recommendations. Samples were kb deletion). Proband BB, heterozygous for the 1.02-kb
electrophoresed in 1% agarose gels and, after ethidium deletion and the splice-site change (IVS14-1GrT), was
bromide staining, were visualized by a UV transillumi- also subjected to RT-PCR analysis, with primers that
nator. ampliﬁed exons 5–15. Two PCR products were ampli-
ﬁed. Sequencing revealed one product to be missing ex-
ons 7 and 8 (corresponding to the 1.02-kb deletion).Results
The other product was shown to have incorrectly spliced
1.02-kb–Deletion Screen exon 15. A cryptic splice-acceptor site in exon 15 was
One hundred eighty-eight unrelated patients with used, which resulted in two in-frame stop codons being
JNCL were screened for the 1.02-kb deletion in order to introduced: GCCCTGGAGtgatgagcaccgggag (sequence
determine the frequency of the common disease-causing in uppercase is exon 14; sequence in lowercase is exon
mutation and to identify patients carrying other muta- 15; and the two stop codons are underlined). The pre-
tions. The 1.02-kb deletion was found to be present dicted translation product is a truncated protein of 399
on 85% of Batten disease chromosomes. Seventy-four amino acids.
percent (139) of the patients were homozygous for the
1.02-kb deletion, 22% (41) were heterozygous, and 4% Discussion
(8) carried other undeﬁned mutations on both chromo-
somes. All results were concordant with the observed A high percentage (96%) of patients were found to
have the 1.02-kb deletion on at least one chromosome,haplotypes for alleles at markers D16S299 and
D16S298. (Mitchison et al. 1993, 1994, 1995; Lerner whereas 49 patients were found to carry other muta-
tions, including three that have been described elsewhereet al. 1994). Forty-nine patients carried mutations other
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Table 2
Novel Mutations Identiﬁed in CLN3
No. of
Parental Families
Nucleotide Amino Acid Change/ Origin of Restriction- with
Familya Haplotypeb Mutationc Changed Predicted Consequenced Locatione Mutationf Site Change Mutation Country/ies of Origin
L39 56g/46h Missense c.302TrC Leu101Pro Exon 5 Maternal BsiHKAI (loss) 1 The Netherlands
L227 56g/54h 2-bp insertion c.374-375insCC Frameshift after Pro126 Exon 6 Maternal . . . 1 United Kingdom
L1 44h/44h 1-bp deletion c.424delG Frameshift after Leu141 Exon 6 Both BstNI (loss) 5 The Netherlands (3), United States (2) i
L121/BA 56g/64h Intron change IVS6-13GrC Aberrant splicing j Intron 6 Paternal . . . 1 United States
Truncated protein
L29 56g/66h Nonsense c.482CrG Ser161STOP Exon 7 Maternal Sau3A (gain) 1 Sweden
L259 45g/32h Nonsense c.485CrG Ser162STOP Exon 7 Maternal NlaIII (gain) 1 Denmark
L46 56g/64h Missense c.509TrC Leu170Pro Exon 7 Maternal . . . 1 United Kingdom
L116 66h/66h 2-bp deletion c.558delAG Frameshift after Ser185 Exon 8 Both AlwNI (loss) 1 Italy
L250 n3h/n3h 1-bp insertion c.586-587insG Frameshift after Gly195 Exon 8 ND . . . 1 United Kingdom
L189 44k/34h Nonsense c.631CrT Gln211STOP Exon 8 Maternal AccI (gain) 1 Italy
L285 n6g/n6h Missense c.883GrA Glu295Lys Exon 11 Maternal . . . 1 Finland
L209 63h/63h 1-bp insertion c.944-945insA Frameshift after Ser314 Exon 12 Both HincII (gain) 4 Italy (2), Iceland, United States i
L243 26g/43h Nonsense c.979CrT Gln327STOP Exon 13 Maternal BfaI (gain) 1 Denmark
L216 56g/66h Missense c.988GrT Val330Phe Exon 13 Maternal . . . 1 Norway
L10 56g/66h Missense c.1000CrT Arg334Cys Exon 13 Paternal BsrBI (loss) 3 The Netherlands (3)
L204 56g/45h Missense c.1001GrA Arg334His Exon 13 Paternal BsrBI (loss) 4 Finland, United Kingdom, Germany,
United States i
L8 56g/54h Nonsense c.1054CrT Gln352STOP Exon 13 Maternal PstI (loss) 2 The Netherlands, United States i
BB 56g/26h Splice site IVS14-1GrT Aberrant splicing j Intron 14 Maternal . . . 1 United States i
Truncated protein
L61 56g/63h 1-bp deletion c.1272delG Frameshift after Ser423 Exon 15 ND . . . 1 United Kingdom
a Family in which mutation originally was found.
b Formed by markers D16S299 and D16S298.
c None of the missense or the intronic mutations is present on 90 normal chromosomes, by sequencing.
d Numbering is according to Antonarakis’s (1996) recommendations for a nomenclature system for human genome mutations (http://ariel.ucs.unimelb.edu.au:80/Çcotton/antonara.htm).
e Numbering is that of Mitchison et al. (1997).
f ‘‘ND’’ denotes that it was not possible to conﬁrm the parental origin of the mutation.
g 1.02-kb Deletion is present.
h Novel mutation is present.
i Both parents are of northern-European ethnic origin.
j Conﬁrmed by RT-PCR analysis and sequencing.
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Figure 1 Schematic representation of locations of mutations in CLN3. A, Designation of mutations, according to Antonarakis’s (1996)
recommendations for a nomenclature system for human gene mutations (http://ariel.ucs.unimelb.edu.au:80/Çcotton/antonara.htm). Mutations
identiﬁed above the cDNA are point mutations in the ORF; those below are deletions, insertions, or point mutations in introns. Missense
mutations are in boldface, and intronic mutations are in italics. The location of the four previously reported mutations (The International
Batten Disease Consortium 1995) are indicated by dotted lines; three are large genomic deletions; the deleted nucleotides shown relate to the
cDNA only. B, Location of the six missense mutations identiﬁed in this study, shown on the predicted structure of CLN3 protein (Janes et al.
1996). Amino acid numbering is according to recommendations for a nomenclature system for human gene mutations (http://ariel.ucs.unimelb
.edu.au:80/Çcotton/antonara.htm).
(The International Batten Disease Consortium 1995). promoter region or elsewhere in an intron. Analysis of
these regions is underway.Sequence analysis of the CLN3 open-reading frame in
the 46 patients with other mutations resulted in the char- Eleven of the newly identiﬁed mutations can be de-
acterization of 19 new mutations. The predicted effects tected by use of a restriction-digestion test (table 2).
of two mutations (intronic and splice site) were con- These tests can now be used, in conjunction with the
ﬁrmed by RT-PCR analysis. Further analysis will be nec- 1.02-kb deletion assay, to conﬁrm JNCL in newly diag-
essary to determine the cellular consequences of the mu- nosed families and will allow both easier presymptom-
tations. atic testing of siblings and carrier testing.
The mutations in 32/46 patients were delineated in A founder effect is associated with the 1.02-kb dele-
this study; mutations on both chromosomes were identi- tion. All chromosomes carrying this deletion have, for
ﬁed in 31/46. Therefore, the disease-causing mutations alleles at markers D16S299-D16S298, either haplotype
in 92% (173/188) of the patients in our resource were ‘‘56’’ or a related haplotype (Mitchison et al. 1993,
1994, 1995; Lerner et al. 1994). Of the 19 novel muta-deﬁned, making a total of 23 disease-causing mutations
reported, to date, in CLN3. Mutations were not found tions identiﬁed in this study, the majority are ‘‘private,’’
occurring in only one family. However, ﬁve mutationsin 14 patients with classical JNCL (13 of these patients
were heterozygous for the 1.02-kb deletion, and 1 does occur in more than one family (table 2), and all families
with the same mutation have identical or related haplo-not have the 1.02-kb deletion on either chromosome).
All coding regions have been sequenced in these patients, types. This suggests the existence of smaller founder ef-
fects, two of which (c.424delG/haplotype‘‘44’’ andand the results suggest that mutations must lie in the
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c.1000CrT/haplotype‘‘66’’) are concentrated in the romyces cerevisiae (YHC3) (GenBank accession number
Z49334), dog (GenBank accession number L76281),Dutch population and three of which (c.944-945insA/hap-
lotype‘‘63,’’ c.1000GrA/haplotype‘‘46,’’ and c.1054CrT/ and mouse (GenBank accession number U47106) (Lee
et al. 1996). Five of the six residues are conserved inhaplotype‘‘54’’) are more widespread.
The majority (163/174) of patients with JNCL in Caenorhabditis elegans (GenBank accession number
Z77656). A structural model for the Batten disease pro-whom mutations have been identiﬁed have, on both
chromosomes, mutations that are predicted to give rise tein has recently been proposed (Janes et al. 1996). The
location of the missense mutations identiﬁed in the pres-to truncated proteins. All of these patients have the clas-
sical JNCL phenotype. The 11 remaining patients are ent study are shown in ﬁgure 1B. Two are located in
predicted transmembrane segments, and four are locatedheterozygous for the 1.02-kb deletion and a missense
mutation. Eight are heterozygous for missense muta- on predicted extracellular loops on one face of the pro-
tein only. This suggests that one face of the CLN3 pro-tions affecting either residue 330 or residue 334: seven of
these have classical JNCL, whereas one (patient L204Pa) tein is of particular functional importance. Except for
one possible exception (patient L204Pa), patients withhas an atypical phenotype. Since patient L204Pa is 15
years old, it is still too early in the disease course to missense mutations affecting amino acid residues 330
and 334 (ﬁg. 1B) all have the classical JNCL phenotype,predict ﬁnal disease severity. The three remaining pa-
tients are heterozygous for three different missense mu- whereas patients with the other three missense muta-
tions all have an atypical clinical course. This indicatestations, and all have an atypical phenotype. The ﬁrst of
these patients, L39Pa, has nonclassical JNCL, diagnosed that amino acid residues 330 and 334 must be critical
for normal function of the CLN3 protein. The identiﬁ-on the basis of the fact that the patient remained conver-
sant until death at age 25 years (see Patients and Meth- cation of such residues will greatly facilitate the determi-
nation of the important structural and functional do-ods). The other two patients, L46Pb and L285Pa, are
nowú20 years of age and are therefore late in the course mains of the CLN3 protein.
of their disease. Both have a phenotype that is domi-
nated by visual failure, which suggests that the spectrum
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